Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback